Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven Advanced Papillary Renal Cell Carcinoma
NCT05043090Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 25
01
Overview
A Phase 3 trial of savolitinib, durvalumab in papillary renal cell carcinoma (PRCC), sponsored by AstraZeneca. Started Oct 2021; status: active, not recruiting.
02
Drugs
savolitinibdurvalumab
03
Conditions
papillary renal cell carcinoma (PRCC)
Beyond the preview
Go deeper on NCT05043090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05043090.